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Activin A stimulated insulin secretion in rat pancreatic islets, an effect that was attenuated by reduction of extracellular Ca2’ and abolished by 
either nitrendipine or verapamil. Activin A increased intracellular the free Ca” concentration, [Ca’+],, in fura-2-loaded islets. Activin A-mediated 
elevation of [Ca*+], was abolished by the reduction of extracellular Ca” or the addition of nifedipine. In addition, activin A did not increase [Ca*‘], 
in the presence of d&oxide, an opener of ATP-sensitive K+ channels. These results suggest hat activin A increases insulin secretion by stimulating 
Ca” entry. 
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1. INTRODUCTION 
Activin A is a homodimeric protein with molecular 
weight of 25 kDa originally isolated from ovarian fluid 
as a stimulator of secretion of follicle-stimulating 
hormone [l]. The structure of activin A resembles, in 
many aspects, that of transforming growth factor-j? 
(TGF-B), and it is now considered to be a member of 
the TGF-/? supergene family. Accordingly, activin A 
elicits a variety of effects in many types of cells and, in 
particular, modifies cellular growth and differentiation 
as an autocrine or paracrine factor [2-6]. 
We reported previously that activin A augmented in- 
sulin secretion in rat pancreatic islets [7]. When studied 
in a perifusion system [8], it induced a biphasic secretory 
response of insulin in the presence of 2.8 mM glucose. 
Of interest is the a fact that immunoreactivity to activin 
A exists in pancreatic islets [8,9]. Immunoreactive ac- 
tivin A localizes mainly in secretory granules in cc-cells. 
Furthermore, activin A and glucagon co-exist in the 
same secretory granules in a-cells and both may be 
released simultaneously. These results raise the possibil- 
ity that activin A may play a physiological role in the 
regulation of insulin secretion. 
Previous studies in our laboratory demonstrate that 
activin A affects cellular Ca” metabolism. For example, 
in erythroleukemia cells and in isolated hepatocytes, 
activin A increases intracellular free Ca2+ concentra- 
tions, [Ca2+],, by causing breakdown of phosphoinosi- 
tides [lO,l 11. In pituitary FSH secreting cells, activin A 
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increases [Ca’+]i, but the effect is totally dependent on 
extracellular Ca2+ [12]. Since intracellular Ca2+ is a pri- 
mary regulator of insulin secretion in j&ells of pancre- 
atic islets [ 131, it is of interest o examine whether activin 
A affects cellular Ca2’ metabolism in /?-cells. The pres- 
ent study was conducted to address this issue. The re- 
sults indicate that activin A causes insulin secretion by 
stimulating Ca2+ entry. 
2. MATERIALS AND METHODS 
2.1. Preparation of islets and measurement of insulin secretion 
Pancreatic islets were isolated from male Wistar rats using collage- 
nase according to Lacy and Kostianovski [14]. Islets were suspended 
in modified Kreb’sRinger bicarbonate (KRB) buffer containing 20 
mM HEPES/NaOH (pH 7.4), 5 mM NaHCO,, 2.0 mM Ca2’, 4.5 mM 
K’ and 0.1% bovine serum albumin equilibrated with 100% 0,. Glu- 
cose concentration of the medium was 2.7 mM unless otherwise men- 
tioned. Islets were incubated for 60 min and the supematant was 
stored at -20°C for the measurement of insulin. Insulin was measured 
by radioimmunoassay using rat insulin as standard. 
2.2. Monitoring of intracellular free Cd’ concentration 
Intracellular free Ca*’ concentration ([Ca”],) was monitored by 
measuring fluorescence of fura-2. For loading of fura-2, islets were 
incubated in KRB buffer containing 2 PM fura-2/AM for 30 min at 
room temperature. After loading, islets were attached to a coverglass 
using Cell-tak, and were incubated in KRB buffer containing 50 PM 
probenecid to reduce leakage of fura- [ 151. Fluorescence from a single 
islet was monitored by a microfluorometer as described previously 
[16]. The coverglass was mounted in a fluorescent microscope (Nikon, 
Tokyo, Japan) and was superfused with KRB buffer containing 5OpM 
probenecid at a flow rate of 1 ml/min. The temperature of the peri- 
fusate was 34OC. The islet was excited alternately with 340 and 380 
nm at 60 Hz. Emissions (510 nm) from each excitation wavelength 
were collected, and average of the ratio of two emissions (340/380 nm) 
was calculated every second. The 340/380 ratio was monitored [161 and 
was not calibrated in terms of free Ca2’ concentration since the distri- 
bution of fura- in the islet was not known. 
Published by Elsevier Science Publishers B. K 
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Fig. 1. Effect of glucose on intracellular free Ca*+ concentration. A fura-2-loaded islet was stimulated with 16.7 mM glucose and the 340/380 nm 
ratio was monitored. The result is the representative of ten experiments. 
2.3. Measurement of CAMP 
Islets were incubated for 15 min in KRB buffer containing 0.5 mM 
3-isobutyl-1-methylxanthine and various stimulators. Trichloroacetic 
acid was then added to terminate the reaction. After the removal of 
trichloroacetic acid by washing with diethylether, CAMP was meas- 
ured after succinylation using a radioimmunoassay kit (Yamasa, 
Tokyo, Japan). 
3. RESULTS 
3.1. Effect of reduction of extracellular Ca2’ on activin 
A-induced insulin secretion 
It is well known that Ca2’ plays an essential role in 
the regulation of insulin secretion [13]. We therefore 
examined whether changes in, extracellular Ca2+ would 
affect activin-mediated insulin secretion in a batch incu- 
bation system. In the presence of 2.0 mM extracellular 
Ca2+, 10 nM activin A induced an approximately 3-fold 
increase in insulin secretion. Reduction of extracellular 
Ca2’ attenuated both basal and activin-mediated insulin 
secretion (Table I). When the extracellular CaZC concen- 
Table I 
Effect of reduction of extracellular Ca2+ on activin A-mediated insulin 
secretion 
Extracellular calcium (mM) Insulin @U/h/islet) 
None Activin A 
2.0 29.4 + 6.3 72.4 + 12.1 
1.0 25.3 f 7.1 64.2 f 9.6 
0.5 16.3 f 5.2 23.2 f 6.2 
0.1 6.3 f 2.4 7.4f 2.8 
0.05 2.1 f 1.2 2.5 f 1.0 
Islets were incubated for 60 min with or without 10 nM activin A in 
the presence of varying concentrations of extracellular Ca”. Values 
are the mean + S.E.M. for five experiments. 
tration was 100 PM or less, activin A did not augment 
insulin secretion. 
3.2. Effect of Cd’ channel blockers on activin-mediated 
insulin secretion 
In the next set of experiments, we examined the effect 
of Ca2+ channel blockers on activin-mediated insulin 
secretion. As shown in Table II, nifedipine, a dihy- 
dropyridine antagonist of L-type voltage-dependent 
Ca2+ channels, completely blocked activin-induced in- 
sulin secretion. Similarly, verapamil completely inhib- 
ited the action of activin A in islets. 
3.3. Effect of activin A on intracellular free Cd’ concen- 
tration 
We monitored changes in [Ca’+]i by measuring fura- 
fluorescence in a single islet. Elevation of ambient glu- 
cose to 16.7 mM resulted in an elevation of [Ca2’]i after 
about a 20 s lag period. The initial rise in [Ca”], was 
followed by a sustained plateau phase (Fig. 1). When 10 
Table II 
Effect of Ca’+ channel blocker on activin A-induced insulin secretion 
Addition 
None 
+nifedipine 
+verapamil 
10 nM activin A 
+nifedipine 
+verapamil 
Insulin (W/h/islet) 
34.1 f 4.3 
31.3 It 6.2 
31.8 + 5.3 
66.3 f 7.3* 
36.4 f 9.6** 
39.3 t 8.1** 
Islets were incubated for 60 min with or without 10 nM activin A in 
the presence and absence of either 1 PM nifedipine or 10 PM vera- 
pamil. Values are the mean f S.E.M. for four experiments. Concen- 
tration of extracellular Ca” was 2.0 mM. Statistical analysis was done 
by Student’s t-test. *P < 0.01 vs. none, **P < 0.01 vs. 10 nM activin 
A. 
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Fig. 3. Effect of activin A in the presence of d&oxide. A fura-2-loaded islet was stimulated by 10 nM activin A in the presence of 1OOpM diazoxide. 
nM activin A was added to an islet, a sustained eleva- 
tion of [Ca’+]i was observed. The elevation was detected 
without a lag period, and burst-like elevation of [Ca’+], 
was superimposed on to the sustained phase (Fig. 2A). 
Addition of 1 FM nifedipine to activin A-stimulated 
islets abolished the burst-like elevation of [Ca”], (Fig. 
2B). Activin A did not cause any change in [Ca”], in the 
presence of 10 ,uM extracellular Ca2+ (Fig. 2C). Under 
similar conditions, 10 PM carbachol induced an im- 
mediate increase in [Ca”], (Fig. 2D). When the plasma 
membrane of the @cells was hyperpolarized by adding 
100 PM diazoxide, an opener of ATP-sensitive K+ chan- 
nels, [Ca2’], was decreased slightly: under these condi- 
tions, activin A did not cause any change in [Ca’+], 
(Fig. 3). 
3.4. Effect of activin A on CAMP 
As shown in Table III, 10 nM glucagon induced a 
marked increase in CAMP in islets in the presence of 
3-isobutyl-1-methylxanthine. Under similar conditions, 
activin A did not affect cellular CAMP. 
4. DISCUSSION 
The present results demonstrate for the first time that 
activin A increases [Ca”], in rat pancreatic islets. Al- 
though we monitored [Ca”], in a single islet, which con- 
tains multiple types of cells, the elevation of [Ca”], pre- 
sumably reflects [Ca”]i in /?-cells for the following rea- 
sons. First, /?-cells are the most abundant cells in the 
islet and [Ca2+]i response to high glucose, which occurs 
in &cells, is in fact detected in our system. Second, the 
t 
Fig. 2. Effect of activin A on intracellular free Ca” concentration. 
(A,B) A fura-2-loaded islet was stimulated with 10 nM activin A, and 
1 PM nifedipine was added as indicated (B). (CD) A fura-2-loaded 
islet was stimulated by 10 nM activin A (C) or 10 PM carbachol (D) 
in the presence of 10 PM extracellular Ca2’. The results are represen- 
tative of at least three experiments with similar results. 
increase in [Ca”]i in response to activin A is accompa- 
nied by an enhancement of insulin secretion. Con- 
versely, insulin secretion is attenuated when activin-me- 
diated elevation of [Ca2’]i s blocked by nitrendipine. 
Thirdly, d&oxide, which activates ATP-sensitive K’ 
channel in /I-cells, reverses the action of activin A on 
[Ca’+]i 
The present results indicate that activin A appears to 
stimulate insulin secretion by increasing [Ca2+]i in /I- 
cells. The action of activin A is completely blocked by 
an addition of a dihydropyridine Ca2+ channel blocker, 
nifedipine, or by reducing extracellular Ca2+. This is in 
contrast to the action of carbachol, which causes break- 
down of phosphoinositide [17] and increases [Ca”], 
mainly by causing release of Ca2+ from intracellular 
pools. It is therefore unlikely that activin A increases 
[Ca”], by causing phosphoinositide turnover. Presuma- 
bly, activin A may increase [Ca2’], by stimulating Ca2+ 
entry via voltage-dependent Ca2’ channels. Consistent 
with this idea is the a fact that diazoxide, which hyper- 
polarizes the plasma membrane, attenuates the action 
of activin A on [Ca2’], It should be mentioned, however, 
that our results do not address the involvement of ATP- 
sensitive K’ channels in the action of activin A. It is 
reported that agents which increase CAMP elevate 
[Ca2+], by stimulating Ca2’ influx [18], yet, as shown in 
Table III 
Effect of activin A and glucagon on CAMP 
Addition CAMP (pmoU30 mm/islet) 
None 0.45 f 0.15 
Activin A 0.51 r 0.20 
Glucagon 5.81 + 1.20 
Islets were incubated for 30 min with either 10 nM activin A or 10 nM 
glucagon and CAMP was measured. Values are the mean f S.E.M. for 
five experiments. 
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Table III, activin A does not augment production of 
CAMP. Taken together, the effect of activin A on islet 
Ca*’ metabolism is quite unique in that it stimulates 
Ca*+ entry by a mechanism independent of CAMP. 
Since the action of activin A is blocked by dihy- 
dropyridine, it is likely that activin A activates, either 
directly or indirectly, voltage-dependent Ca*+ channels. 
We have reported recently that activin A increases 
[Ca*‘]i by stimulating Ca*’ influx in FSH-se- 
creting pituitary tumor cells [12]. In these cells, activin 
A stimulates Ca*’ entry by causing depolarization and 
thereby activating voltage-dependent Ca*+ channels 
[19]. It is tempting to speculate that activin A stimulates 
Ca*’ entry by changing the membrane potential in pan- 
creatic B-cells. Further study is required to elucidate the 
mechanism of action of activin A in islet /I-cells. 
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